Stability of blood eosinophils in COPD and controls and the impact of eosinophil count, age, gender and smoking status

Date of Approval
Application Number
16_131
Technical Summary

Rationale: Chronic Obstructive disease is an inflammatory disease which is known to affect the airways of the lungs. Pathophysiology of the disease is mediated by release of macrophages, eosinophils, neutrophils , cytokine, and CD8+ lymphocytes. Peripheral eosinophil counts are increasingly recognised as a biomarker for response to inhaled corticosteroids in COPD and may assist in better targeting treatments to patients who will benefit most. However, little is known about the long-term stability of blood eosinophils in COPD and the impact of age, gender and eosinophil counts. Greater understanding of this subject area can help gain better understanding needed to tailor COPD treatments to specific patient groups, potentially reducing the cost of managing the disease and increasing the chance of improved outcomes.
Objective: The study therefore aims to determine the stability of blood eosinophil counts in COPD patients and non-COPD patients.
Methods: The primary outcome will be the stability of blood eosinophil count, with stability defined as a count remaining persistently at <2% or >/= 2%. Patients will be followed until end of study period, or when defined as unstable ("failure"). Kaplan Meier curves will be plotted to show eosinophil stability, stratified by eosinophil counts at baseline age groups, gender, and smoking status.

Health Outcomes to be Measured

Stability of blood eosinophil count

Collaborators

Frank de Vries - Chief Investigator - Utrecht University
Andrea Burden - Collaborator - ETH Zurich
Anke-Hilse Maitland-van der Zee - Collaborator - University of Amsterdam
Dionne Braeken - Collaborator - Utrecht University
Frits Franssen - Collaborator - CIRO
Miel (Emiel) Wouters - Collaborator - CIRO
Olorunfemi Oshagbemi - Collaborator - Utrecht University
Yvonne Henskens - Collaborator - Maastricht University